Which companies are Jinghua Pharmaceutical's closest peers?

The cockpit's peer set: CARsgen Therapeutics (2171.HK), Zhejiang Int'l (000411.SZ), Sanofi Consumer Healthcare India (SANOFICONR.NS), Latigo Biotherapeutics (LTGO), Luye Pharma (2186.HK), Chongqing Pharscin Pharmaceutical (002907.SZ), Guizhou Xinbang Pharmaceutical (002390.SZ), Alumis (ALMS).

How has Jinghua Pharmaceutical stock performed?

Over six months to 6 Nov 2026 the shares returned -7.7% against -9.5% for the median peer; over one year -8.6%.

← CockpitCompetitor Analysis › 002349.SZ Jinghua Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Jinghua Pharmaceutical Group Co., Ltd. Class A002349.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Momentum strong 65

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$825M

US dollars, full cap

Free float

61%

of shares outstanding

$/day

$47.5M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

+4.8 pp

WACC 5.2%

Hurdle

-4 pp

Req g minus delivered

Close · CNYCN¥6.94

1D-2.7%

1W+1.5%

1M-20.4%

3M+2.2%

6M-7.7%

YTD-4.4%

1Y-8.6%

ATR %5.3%

52w lowhigh27.6% off high

What Jinghua Pharmaceutical does

Employees: 1,462

Jinghua Pharmaceutical at a glance

Size Jinghua Pharmaceutical (002349.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $825M, the 2682nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.94 on 6 Nov 2026.

Performance Over six months the shares fell 7.7%, against -9.5% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 1.9% over the last twelve months (peer median +2.2%); the operating margin is 19.9% (peer median 10.1%).

Valuation It trades at 3.2× enterprise value to sales against a peer median of 2.4× (9th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.8 points above its cost of capital (5.2% WACC).

Relative performance

Six months, rebased to 100: Jinghua Pharmaceutical against the median of its 20 peers (local-currency closes).

Jinghua Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥1.48B	CN¥1.45B	CN¥1.39B	CN¥1.50B	CN¥1.56B
Revenue growth	—	+4%	-7%	-4%	—
Gross profit	CN¥814M	CN¥726M	CN¥665M	CN¥702M	CN¥681M
EBITDA	n/a	CN¥347M	CN¥300M	CN¥372M	CN¥323M
Net income	CN¥233M	CN¥219M	CN¥213M	CN¥248M	CN¥212M
Free cash flow	CN¥270M	CN¥326M	CN¥290M	CN¥270M	CN¥305M
Capital expenditure	CN¥30.4M	CN¥20.3M	CN¥30.9M	CN¥28.4M	CN¥61.6M
Total debt	CN¥13.9M	CN¥77.3M	CN¥35.0M	CN¥36.0M	CN¥39.2M

Quarterly statements and history in the cockpit →

Jinghua Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Jinghua Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jinghua Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jinghua Pharmaceutical is the large dot.

Jinghua Pharmaceutical competitors and peer comparison

How Jinghua Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jinghua Pharmaceutical against its 20 peers (data as of 6 Nov 2026)
Measure	002349.SZ	Peer median	Rank in peer set
1-month return	-20.4%	-2.0%	2nd lowest of 21
6-month return	-7.7%	-9.5%	8th highest of 20
Distance from 52-week high	-27.6%	-32.8%	7th highest of 21
Revenue growth (TTM)	+1.9%	+2.2%	10th highest of 19
Operating margin	19.9%	10.1%	4th highest of 19
EV / Sales	3.2×	2.4×	9th most expensive of 19
Growth the price implies (Req g, 7 yrs)	-1.8%	4.8%	4th least demanding of 12
Growth delivered (Del g)	+2.6%	+2.1%	6th highest of 12
Hurdle (Req g minus delivered)	-4.5 pp	-5.6 pp	6th most demanding of 12
ROIC minus cost of capital	+4.8 pp	-1.7 pp	4th highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Jinghua Pharmaceutical 002349.SZ	China	$825M	-8%	+2%	20%	3.2×	-1.8%	+2.6%
CARsgen Therapeutics 2171.HK	Hong Kong	$825M	-54%	+68%	-170%	32.3×	n/a	n/a
Zhejiang Int'l 000411.SZ	China	$828M	-8%	+3%	3%	0.3×	n/a	n/a
Sanofi Consumer Healthcare India SANOFICONR.NS	India	$835M	-28%	+23%	36%	8.1×	17.1%	+22.7%
Latigo Biotherapeutics LTGO	United States	$835M	n/a	n/a	n/a	n/a	n/a	n/a
Luye Pharma 2186.HK	Hong Kong	$839M	-36%	+3%	18%	1.2×	-10.5%	+1.9%
Chongqing Pharscin Pharmaceutical 002907.SZ	China	$808M	-7%	+8%	10%	5.7×	10.7%	-1.4%
Guizhou Xinbang Pharmaceutical 002390.SZ	China	$805M	-10%	-13%	4%	0.9×	-3.0%	-0.8%
Alumis ALMS	United States	$805M	-27%	-63%	-5,480%	45.8×	n/a	n/a
SK Discovery 006120.KS	South Korea	$804M	+11%	+20%	3%	0.8×	n/a	n/a
Zhejiang Anglikang Pharmaceutical 002940.SZ	China	$801M	-19%	-6%	10%	4.2×	18.2%	+2.1%
Knight Therapeutics GUD.TO	Canada	$800M	+37%	+42%	5%	1.9×	9.5%	+17.7%
Sanofi India SANOFI.NS	India	$800M	-3%	-6%	26%	4.2×	16.5%	-8.7%
Kaken Pharmaceutical 4521.T	Japan	$854M	-8%	-7%	11%	0.9×	n/a	n/a
Annexon ANNX	United States	$796M	-26%	n/a	n/a	n/a	n/a	n/a
Suven Life Sciences SUVEN.NS	India	$792M	+20%	+17%	-4,228%	849.2×	n/a	n/a
Lexicon Pharmaceuticals LXRX	United States	$792M	-11%	-29%	-131%	15.9×	n/a	n/a
Katakura Industries 3001.T	Japan	$791M	+46%	0%	16%	2.5×	0.2%	+0.5%
Hygeia Healthcare 6078.HK	Hong Kong	$861M	-7%	+2%	14%	1.9×	4.8%	+22.5%
Hunan Jiudian Pharmaceutical 300705.SZ	China	$789M	-18%	-5%	13%	1.9×	-1.1%	+26.1%
Collegium Pharmaceutical COLL	United States	$788M	-36%	+14%	20%	2.3×	-7.0%	+20.3%

Questions

Which companies are Jinghua Pharmaceutical's closest peers?: The cockpit's peer set: CARsgen Therapeutics (2171.HK), Zhejiang Int'l (000411.SZ), Sanofi Consumer Healthcare India (SANOFICONR.NS), Latigo Biotherapeutics (LTGO), Luye Pharma (2186.HK), Chongqing Pharscin Pharmaceutical (002907.SZ), Guizhou Xinbang Pharmaceutical (002390.SZ), Alumis (ALMS).
Is Jinghua Pharmaceutical expensive compared with its peers?: On ev / sales it trades at 3.2× against a peer median of 2.4×, 9th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about -2% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Jinghua Pharmaceutical stock performed?: Over six months to 6 Nov 2026 the shares returned -7.7% against -9.5% for the median peer; over one year -8.6%.